548 Results for "

KIT/PDGFRA-driven GIST

" in MedChemExpress (MCE) Product Catalog:
Products (548)

548 Results for "KIT/PDGFRA-driven GIST" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-15463R
CAS No.: 152459-95-5
Synonyms: STI571 (Standard); CGP-57148B (Standard)
Research Areas:  

Cancer

Imatinib (Standard) is the analytical standard of Imatinib. This product is intended for research and analytical applications. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
Cat. No.: HY-18187
CAS No.: 516523-31-2
Target:  

Apoptosis

Research Areas:  

Cancer

Ki 23057 is a competitive, orally active inhibitor for tyrosine kinase, which inhibits the phosphorylation of K-samII/FGF-R2, VEGF-R1, VEGF-R2, PDGF-Rβ and c-Kit, with IC50s of 88, 69, 83, 100 and 480 nM. Ki 23057 inhibits the proliferation of sclerogastric cancer cells OCUM-2MD3 and OCUM-8, and induces apoptosis. Ki 23057 exhibits antitumor efficacy in mouse models .
loading...
    loading...
Cat. No.: HY-184327
Research Areas:  

Inflammation/Immunology

Anti-inflammatory agent 117 is an orally active anti-inflammatory agent and c-Kit kinase inhibitor with an IC50 of 15.2 μM. Anti-inflammatory agent 117 blocks the NF-κB signaling pathway and inhibits the release of IL-6. Anti-inflammatory agent 117 exhibits anti-inflammatory effects in mouse models of acute lung injury, sepsis and ulcerative colitis. Anti-inflammatory agent 117 can be used in research related to acute lung injury, sepsis and ulcerative colitis .
loading...
    loading...
Cat. No.: HY-18949
CAS No.: 856436-16-3
Target:  

FLT3 JAK c-Kit

Research Areas:  

Cancer

JI6 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ~40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits JAK3 and c-Kit, with IC50s of ~250 and ~500 nM, respectively. JI6 can be used for the research of acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-KD1103
Red Fluorescent Rapid Labelling Kit (CY3) enables red fluorescent labelling of proteins. Maximum excitation/ Emission Wavelength: 550/570 nm. Based on NHS ester chemistry, the NHS ester-activated fluorescent dye reacts with primary amines in the antibody/protein to be labelled at pH 7-9, forming stable amide bonds to achieve conjugation with the antibody/protein. Typically, one IgG molecule can bind 2–8 molecules of CY3. The entire experiment can be completed within 2 hours.
loading...
    loading...
Cat. No.: HY-KD1104
Red Fluorescent Rapid Labelling Kit (AF555) enables red fluorescent labelling of proteins. Maximum excitation/ Emission Wavelength: 555/565 nm. Based on NHS ester chemistry, the NHS ester-activated fluorescent dye reacts with primary amines in pH 7-9 solutions to form stable amide bonds with the target antibody/protein, achieving conjugation. Typically, one IgG molecule can bind 2-8 molecules of AF555. The entire procedure can be completed within two hours.
loading...
    loading...
Cat. No.: HY-KD1107
Deep Red Fluorescent Rapid Labelling Kit (CY5) enables red fluorescent labelling of proteins. Maximum excitation/ emission wavelengths: 649/667 nm. Based on NHS ester chemistry, the NHS ester-activated fluorescent dye reacts with primary amines in the antibody/protein to be labelled at pH 7-9, forming stable amide bonds to achieve conjugation. Typically, one IgG molecule can bind 2–8 molecules of CY5. The entire experiment can be completed within 2 hours.
loading...
    loading...
Cat. No.: HY-KD1109
Near-infrared Fluorescent Rapid Labelling Kit (CY7) enables red fluorescent labelling of proteins. Maximum excitation/ emission wavelengths: 750/773 nm. Based on NHS ester chemistry, the NHS ester-activated fluorescent dye reacts with primary amines in the antibody/protein to be labelled at pH 7-9, forming stable amide bonds to achieve conjugation. Typically, one IgG molecule can bind 2–8 molecules of CY7. The entire experiment can be completed within 2 hours.
loading...
    loading...
Cat. No.: HY-KD1111
Near-infrared Fluorescent Rapid Labelling Kit (AF750) enables red fluorescent labelling of proteins. Maximum excitation/ Emission Wavelength: 750/775 nm. Based on NHS ester chemistry, the NHS ester-activated fluorescent dye reacts with primary amines in pH 7-9 solutions to form stable amide bonds, thereby achieving conjugation with antibodies/proteins. Typically, one IgG molecule can bind 2-8 molecules of AF750. The entire procedure can be completed within two hours.
loading...
    loading...
Cat. No.: HY-KD1102
Green Fluorescent Rapid Labelling Kit (AF488) enables green fluorescent labelling of proteins. Maximum excitation/ emission wavelengths: 480/525 nm. Based on NHS ester chemistry, the NHS ester-activated fluorescent dye reacts with primary amines in pH 7-9 solutions to form stable amide bonds, thereby achieving conjugation with antibodies/proteins. Typically, one IgG molecule can bind 2-8 molecules of AF488. The entire procedure can be completed within two hours.
loading...
    loading...
Cat. No.: HY-KD1105
Red Fluorescent Rapid Labelling Kit (AF594) enables red fluorescent labelling of proteins. Maximum excitation/ Emission Wavelength: 594/617 nm. Based on NHS ester chemistry, the NHS ester-activated fluorescent dye reacts with primary amines in pH 7-9 solutions to form stable amide bonds, thereby achieving conjugation with antibodies/proteins. Typically, one IgG molecule can bind 2-8 molecules of AF594. The entire procedure can be completed within two hours.
loading...
    loading...
Cat. No.: HY-K2034

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies.

loading...
    loading...
Cat. No.: HY-13016R
CAS No.: 849217-68-1
Synonyms: XL184 (Standard); BMS-907351 (Standard)
Cabozantinib (Standard) is the analytical standard of Cabozantinib. This product is intended for research and analytical applications. Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .
loading...
    loading...
Cat. No.: HY-150026
CAS No.: 2095628-21-8
Research Areas:  

Cancer

Multi-kinase-IN-2 (compound 7h) is an orally active and potent angiokinase inhibitor. Multi-kinase-IN-2 exhibits excellent inhibitory activity against angiokinases including VEGFR-1/2/3, PDGFRα/β, and FGFR-1, as well as LYN and c-KIT kinases. Multi-kinase-IN-2 significantly attenuates phosphorylation of AKT and ERK proteins. Multi-kinase-IN-2 induces cell apoptosis. Multi-kinase-IN-2 shows anticancer activity .
loading...
    loading...
Cat. No.: HY-16961A
CAS No.: 2244864-88-6
Synonyms: MGCD516 malate; MG-516 malate
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
loading...
    loading...
Cat. No.: HY-170517
CAS No.: 3065631-84-4
Target:  

Wee1 Ephrin Receptor

Research Areas:  

Cancer

PKMYT1-IN-8 (Compound 137) is the inhibitor for PKMYT1 with an IC50 of 9 nM. PKMYT1-IN-8 inhibits EPHB3, EPHA1, KIT, EPHB1, EPHA2, EPHA3, and EPHB2with IC50s of 1.79, 3.17, 4.29, 6.32, 6.83, 8.10, and 10.9 μM, respectively. PKMYT1-IN-8 inhibits the proliferation of cancer cell OVCAR3 with GI50 of 2.02 μM .
loading...
    loading...
Cat. No.: HY-W706452
Synonyms: XL184-d4 S-malate; BMS-907351-d4 S-malate
Cabozantinib-d4 (S-malate) (XL184-d4 (S-malate); BMS-907351-d4 (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
loading...
    loading...
Cat. No.: HY-KD1108
Deep Red Fluorescent Rapid Labelling Kit (CY5.5) enables red fluorescent labelling of proteins. Maximum excitation/ emission wavelengths: 678/695 nm. Based on NHS ester chemistry, the NHS ester-activated fluorescent dye reacts with primary amines in the antibody/protein to be labelled at pH 7-9, forming stable amide bonds to achieve conjugation. Typically, one IgG molecule can bind 2-8 molecules of CY5.5. The entire procedure can be completed within two hours.
loading...
    loading...
Cat. No.: HY-KD1110
The Near-Infrared Fluorescence Rapid Labelling Kit (CY7.5) enables red fluorescent labelling of proteins. Maximum excitation/ emission wavelengths: 788/814 nm. Based on NHS ester chemistry, the NHS ester-activated fluorescent dye reacts with primary amines in the antibody/protein to be labelled at pH 7-9, forming stable amide bonds to achieve conjugation. Typically, one IgG molecule can bind 2-8 molecules of CY7.5. The entire procedure can be completed within two hours.
loading...
    loading...
Cat. No.: HY-K0358

MCE Human CD66b+ Cell Positive Selection Kit is designed for the efficient isolation of CD66b+ cells from human peripheral blood single-cell suspensions. CD66b+ cells are first specifically labeled with the CD66b Capture Antibody and subsequently captured using Releasable Magnetic Beads. Following magnetic separation, the beads are detached from the cell surface using Magnetic Beads Release Buffer, resulting in highly purified CD66b+ cells free of residual magnetic bead labeling.

loading...
    loading...